SAR088

inhibits phosphatidylinositol-5-phosphate 4-kinase, type II, beta; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Brummerhop, Harm: 1 article (07/2014)
2.	Czechtizky, Werngard: 1 article (07/2014)
3.	Langer, Thomas: 1 article (07/2014)
4.	Li, Ziyu: 1 article (07/2014)
5.	Petry, Stefan: 1 article (07/2014)
6.	Rudolph, Christine: 1 article (07/2014)
7.	Schaefer, Hans-Ludwig: 1 article (07/2014)
8.	Schiffer, Alexander: 1 article (07/2014)
9.	Voss, Marc D: 1 article (07/2014)

1.	Insulin Resistance 07/04/2014 - "Thus, SAR088 represents the first orally available and in vivo active PIP5K2B inhibitor and provides an excellent starting point for the development of potent and selective PIP5K2B inhibitors for the treatment of insulin resistance and diabetes."